Slow Capital Inc. Has $4.18 Million Holdings in Repligen Corporation (NASDAQ:RGEN)

Slow Capital Inc. increased its position in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) by 96.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 32,877 shares of the biotechnology company's stock after buying an additional 16,117 shares during the period. Slow Capital Inc. owned about 0.06% of Repligen worth $4,183,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Rice Hall James & Associates LLC increased its holdings in Repligen by 26.4% during the 1st quarter. Rice Hall James & Associates LLC now owns 19,449 shares of the biotechnology company's stock worth $2,475,000 after purchasing an additional 4,058 shares during the last quarter. Louisiana State Employees Retirement System increased its holdings in shares of Repligen by 0.7% in the 1st quarter. Louisiana State Employees Retirement System now owns 14,600 shares of the biotechnology company's stock valued at $1,858,000 after acquiring an additional 100 shares during the last quarter. Stephens Investment Management Group LLC increased its holdings in shares of Repligen by 0.5% in the 1st quarter. Stephens Investment Management Group LLC now owns 539,542 shares of the biotechnology company's stock valued at $68,651,000 after acquiring an additional 2,741 shares during the last quarter. New York State Common Retirement Fund increased its stake in Repligen by 7.6% during the first quarter. New York State Common Retirement Fund now owns 625,388 shares of the biotechnology company's stock valued at $79,574,000 after purchasing an additional 43,946 shares during the last quarter. Finally, Diversify Wealth Management LLC increased its stake in Repligen by 11.2% during the first quarter. Diversify Wealth Management LLC now owns 3,717 shares of the biotechnology company's stock valued at $518,000 after purchasing an additional 375 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on RGEN. JPMorgan Chase & Co. lowered their target price on Repligen from $200.00 to $190.00 and set an "overweight" rating for the company in a report on Tuesday, April 29th. Barclays assumed coverage on Repligen in a research note on Tuesday, June 24th. They set an "overweight" rating and a $150.00 price objective for the company. Evercore ISI lowered their price target on shares of Repligen from $140.00 to $130.00 and set an "in-line" rating for the company in a research report on Tuesday, July 8th. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a research report on Monday, May 5th. Finally, Wolfe Research upgraded shares of Repligen from a "peer perform" rating to an "outperform" rating and set a $160.00 target price for the company in a research report on Tuesday, April 29th. Five analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $170.75.

Repligen Price Performance

Shares of NASDAQ:RGEN traded up $1.65 during trading hours on Wednesday, hitting $119.75. 677,237 shares of the company's stock traded hands, compared to its average volume of 728,793. The company has a market cap of $6.73 billion, a price-to-earnings ratio of -266.11, a price-to-earnings-growth ratio of 3.47 and a beta of 1.11. Repligen Corporation has a 52 week low of $102.97 and a 52 week high of $182.52. The company has a debt-to-equity ratio of 0.27, a quick ratio of 5.79 and a current ratio of 6.79. The company's fifty day simple moving average is $125.01 and its two-hundred day simple moving average is $138.97.

Repligen (NASDAQ:RGEN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, topping analysts' consensus estimates of $0.35 by $0.04. The firm had revenue of $169.17 million during the quarter, compared to analyst estimates of $163.65 million. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The company's revenue was up 10.4% on a year-over-year basis. During the same quarter last year, the business posted $0.28 EPS. As a group, equities analysts anticipate that Repligen Corporation will post 1.72 EPS for the current fiscal year.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.